Breast Cancer

Nerlynx is indicated to treat early-stage HER2-positive breast cancer following trastuzumab-based therapy.

Tumor biology and size should guide breast cancer treatment.

Investigational trastuzumab biosimilar shows promise as potential lower cost treatment option to Herceptin for breast cancer and gastric cancer.

Study findings support research demonstrating endoxifen better inhibits tumor growth compared with tamoxifen.

Women with high cholesterol who take statins were 45% less likely to develop breast cancer.

Small node negative tumors can be aggressive, even if classified as clinical low risk.

Bruce A. Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, discusses the key elements of an effective cancer clinical care pathways program.

Top news of the day from across the healthcare landscape.

Allowing patients to control mammography compression may improve stress associated with breast cancer screening.

Patients with breast cancer who are more rational may strongly consider contralateral mastectomy.

Up to 1.3 million women may not be receiving genetic testing to detect BRCA 1/2 mutations, which increase the risk of certain cancer types.

Self-administered acupressure found to improve sleep and daytime alertness among breast cancer survivors.

The findings highlight the role of Tregs in suppressing the immune response.

Statins may provide a protective effect against breast cancer development.

An estimated 1.2 million American women would likely benefit from recommended genetic test to assess their risk of cancer.

Alcohol consumption results in more than $150 million spent on breast cancer annually.

Fulvestrant is a hormonal therapy that targets the estrogen receptor and helps slow cancer growth.

Faslodex reduced disease progression by 20% among women with HR+, HER2- advanced breast cancer.

Hormone therapy is recommended to treat menopause symptoms, but is not recommended for breast cancer survivors.

Women who worked the night shift found to have a greater risk of developing breast cancer.

Breast cancer treatment may cause women to enter menopause prematurely.

A first-in-class selective retinoic acid receptor alpha agonist is being tested in phase 2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome.

T cell responses in different tumor models are fundamentally similar.

A first-in-class molecule was found to inhibit primary and recurrent breast cancer.

Carolyn Choate journeys 300 miles in a kayak to honor the pharmacologist who created the lifesaving aromatase inhibitor.